CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 1. The effects of activators of PPARs on the viability of human prostatic adenocarcinoma cell lines, DU145, PC-3, and LNCaP. Cells were incubated with 0.01–100 µM linoleic acid (an activator of PPAR-ß), ETYA (an activator of PPAR-{alpha}), and prostaglandin E2 (an inert activator for PPARs); 1–10 µM, 15d-PGJ2; 5–100 µM EPA and DHA; and 2–20 µM, ciglitazone (activators of PPAR-{gamma}); or, vehicle controls (column 0) for 6 days. Viable cells were measured by MTS assay and expressed as a percentage of controls (n = 4–6); bars, SD.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation